TW200611706A - Cytotoxic t lymphocyte - Google Patents

Cytotoxic t lymphocyte

Info

Publication number
TW200611706A
TW200611706A TW093140800A TW93140800A TW200611706A TW 200611706 A TW200611706 A TW 200611706A TW 093140800 A TW093140800 A TW 093140800A TW 93140800 A TW93140800 A TW 93140800A TW 200611706 A TW200611706 A TW 200611706A
Authority
TW
Taiwan
Prior art keywords
antigen
lymphocyte
cytotoxic
peptide
specific
Prior art date
Application number
TW093140800A
Other languages
English (en)
Chinese (zh)
Other versions
TWI374031B (enExample
Inventor
Hiroshi Shiku
Atsunori Hiasa
Satoshi Okumura
Hiroaki Naota
Yoshihiro Miyahara
Original Assignee
Univ Mie
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mie, Takara Bio Inc filed Critical Univ Mie
Publication of TW200611706A publication Critical patent/TW200611706A/zh
Application granted granted Critical
Publication of TWI374031B publication Critical patent/TWI374031B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW093140800A 2004-10-01 2004-12-27 Cytotoxic t lymphocyte TW200611706A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004290785A JP4731867B2 (ja) 2004-10-01 2004-10-01 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法

Publications (2)

Publication Number Publication Date
TW200611706A true TW200611706A (en) 2006-04-16
TWI374031B TWI374031B (enExample) 2012-10-11

Family

ID=36125792

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093140800A TW200611706A (en) 2004-10-01 2004-12-27 Cytotoxic t lymphocyte

Country Status (4)

Country Link
US (3) US20060073126A1 (enExample)
JP (1) JP4731867B2 (enExample)
KR (2) KR20060029591A (enExample)
TW (1) TW200611706A (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
EP2072618A1 (en) * 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
KR20120059581A (ko) * 2009-08-24 2012-06-08 윌슨 울프 매뉴팩처링 다중 종양 항원 또는 다중 바이러스에 대해 특이성을 갖는 ｃｔｌ주의 생성
US20140322344A1 (en) * 2011-08-31 2014-10-30 National University Corporation Tokyo Medical And Dental University Vaccine preparation for cancer treatment
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
IL298359B2 (en) 2015-09-18 2025-12-01 Baylor College Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520543D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3415159B1 (en) 2016-02-08 2023-12-13 Mie University Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumor
US10821134B2 (en) 2017-05-17 2020-11-03 Board Of Regents, The University Of Texas System BK virus specific T cells
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CU20210002A7 (es) 2018-07-10 2021-08-06 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
US10772914B1 (en) 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
CA2425648A1 (en) 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
US20050249743A1 (en) * 2004-01-12 2005-11-10 Thierry Boon-Falleur Isolated peptides which bind to HLA-A24 molecules and uses thereof

Also Published As

Publication number Publication date
US20120238012A1 (en) 2012-09-20
KR20060029591A (ko) 2006-04-06
TWI374031B (enExample) 2012-10-11
US20090068209A1 (en) 2009-03-12
KR101008245B1 (ko) 2011-01-17
US8168191B2 (en) 2012-05-01
KR20100028074A (ko) 2010-03-11
JP2006101735A (ja) 2006-04-20
US20060073126A1 (en) 2006-04-06
US9243227B2 (en) 2016-01-26
JP4731867B2 (ja) 2011-07-27

Similar Documents

Publication Publication Date Title
AR127116A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
PH12021552476A1 (en) Compositions and methods for preparing t cell compositions and uses thereof
MX2018010172A (es) Sistema vector inmunoestimulante novedoso.
NZ602119A (en) Peptide vaccines for cancers expressing tumor-associated antigens
NZ734197A (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
CL2019003423A1 (es) Nuevos péptidos (seq id n°378), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
AR083747A1 (es) Anticuerpos anti-il-23
MX377144B (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
CR20220248A (es) Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer
NZ724296A (en) Antibodies for treatment of cancer expressing claudin 6
MX384422B (es) Vector que expresa conjuntamente vacunas y moléculas coestimuladoras
RU2010110567A (ru) Пептид foxm1 и включающее его медицинское средство
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX2010001086A (es) Nueva inmunoterapia contra tumores neuronales y cerebrales.
MY194571A (en) Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
ATE549398T1 (de) Adoptive immuntherapie mit erhöhter t-lymphozyten-lebensdauer
WO2019160866A3 (en) Compositions and methods for tumor immunotherapy
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
MX375994B (es) Composicion farmaceutica que comprende particulas de plga-peg.
CR20200632A (es) Péptidos restringidos por a*03 par el uso en la inmunoterapia contra el cáncer y métodos relacionados
NZ594198A (en) Neil3 peptides and vaccines including the same
WO2020036646A3 (en) Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees